Rixensart, Belgium

Pierre Vandepapeliere

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Glaxosmithkline Biologicals Sa, Neovacs, Smithkline Beecham Biologicals S.a.. Active years: 2004-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Vandepapeliere. Retrieved from https://idiyas.com/inventor/pierre-vandepapeliere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0


 

Average Co-Inventor Count = 1.5

ph-index = 2

Forward Citations = 44(Granted Patents)


Location History:

  • Rixensart, BE (2004 - 2018)
  • Bonnine, BE (2018)

Company Filing History:


Years Active: 2004-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Pierre Vandepapeliere: Innovator in Vaccine Development

Introduction

Pierre Vandepapeliere is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of immunology, particularly in vaccine development. With a total of four patents to his name, Vandepapeliere's work focuses on enhancing vaccine efficacy through innovative adjuvant compositions.

Latest Patents

Vandepapeliere's latest patents include groundbreaking vaccine compositions that utilize a saponin adjuvant. These inventions provide a human dose of an immunogenic composition that combines an antigen or antigenic preparation with an adjuvant. The adjuvant comprises an immunologically active saponin fraction derived from the bark of Molina, presented in the form of a liposome, along with a lipopolysaccharide. Both components are present in the human dose at levels below 30 µg. This innovative approach aims to improve the immune response to vaccines.

Career Highlights

Throughout his career, Vandepapeliere has worked with prominent companies in the pharmaceutical industry. He has been associated with GlaxoSmithKline Biologicals SA and SmithKline Beecham Biologicals SA. His experience in these organizations has contributed to his expertise in vaccine research and development.

Collaborations

Vandepapeliere has collaborated with esteemed colleagues in the field, including Moncef Mohamed Slaoui and Geraldine Grouard-Vogel. These partnerships have furthered his research and innovation in vaccine technology.

Conclusion

Pierre Vandepapeliere is a distinguished inventor whose work in vaccine development has the potential to significantly impact public health. His innovative approaches to adjuvant compositions demonstrate his commitment to advancing immunology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…